A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy
Identifieur interne : 001B03 ( Main/Corpus ); précédent : 001B02; suivant : 001B04A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy
Auteurs : Anette Schrag ; Shamira Sheikh ; Niall P. Quinn ; Andrew J. Lees ; Caroline Selai ; Chris Mathias ; Irene Litvan ; Anthony E. Lang ; James H. Bower ; David J. Burn ; Philip Low ; Marjan JahanshahiSource :
- Movement Disorders [ 0885-3185 ] ; 2010-06-15.
English descriptors
- KwdEn :
Abstract
The objective of this study was to compare subjective health status and its correlates in progressive supranuclear palsy (PSP) and multiple system atrophy (MSA). One hundred eighty‐eight patients with PSP and 286 patients with MSA completed EQ‐5D and Hospital Depression and Anxiety Scale. The impact on mobility, usual activities, and self‐care was similarly high in both groups after similar duration. Fifty‐six percent of PSP and 43% of MSA had probable depression, and 37% of both groups had probable anxiety. Patients with PSP had significantly higher depression scores, but groups did not differ in anxiety scores. Patients with MSA had significantly greater pain/discomfort than patients with PSP. The most important association with subjective health status was with depressive symptoms, which accounted for 38% and 29% of EQ‐5D variance in patients with PSP and MSA, followed by disease severity and anxiety scores. We conclude that depressive symptoms were common in both disorders, but more severe in PSP. Anxiety symptoms affected 37% of patients in both groups and contributed to impaired subjective health status. Pain was more problematic in MSA than PSP. © 2010 Movement Disorder Society
Url:
DOI: 10.1002/mds.22794
Links to Exploration step
ISTEX:D8D7BC0907EA1442286D43654D717164271E4C8ELe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy</title><author><name sortKey="Schrag, Anette" sort="Schrag, Anette" uniqKey="Schrag A" first="Anette" last="Schrag">Anette Schrag</name><affiliation><mods:affiliation>Institute of Neurology, University College London, London</mods:affiliation></affiliation></author><author><name sortKey="Sheikh, Shamira" sort="Sheikh, Shamira" uniqKey="Sheikh S" first="Shamira" last="Sheikh">Shamira Sheikh</name><affiliation><mods:affiliation>Institute of Neurology, University College London, London</mods:affiliation></affiliation></author><author><name sortKey="Quinn, Niall P" sort="Quinn, Niall P" uniqKey="Quinn N" first="Niall P." last="Quinn">Niall P. Quinn</name><affiliation><mods:affiliation>Institute of Neurology, University College London, London</mods:affiliation></affiliation></author><author><name sortKey="Lees, Andrew J" sort="Lees, Andrew J" uniqKey="Lees A" first="Andrew J." last="Lees">Andrew J. Lees</name><affiliation><mods:affiliation>Institute of Neurology, University College London, London</mods:affiliation></affiliation></author><author><name sortKey="Selai, Caroline" sort="Selai, Caroline" uniqKey="Selai C" first="Caroline" last="Selai">Caroline Selai</name><affiliation><mods:affiliation>Institute of Neurology, University College London, London</mods:affiliation></affiliation></author><author><name sortKey="Mathias, Chris" sort="Mathias, Chris" uniqKey="Mathias C" first="Chris" last="Mathias">Chris Mathias</name><affiliation><mods:affiliation>Institute of Neurology, University College London, London</mods:affiliation></affiliation><affiliation><mods:affiliation>Neurovascular Medicine Unit, Faculty of Medicine, Imperial College London, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Litvan, Irene" sort="Litvan, Irene" uniqKey="Litvan I" first="Irene" last="Litvan">Irene Litvan</name><affiliation><mods:affiliation>Movement Disorder Program, Department of Neurology, University of Louisville, Louisville, Kentucky, USA</mods:affiliation></affiliation></author><author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name><affiliation><mods:affiliation>Division of Neurology, Toronto Western Hospital and the University of Toronto, Toronto, Ontario, Canada</mods:affiliation></affiliation></author><author><name sortKey="Bower, James H" sort="Bower, James H" uniqKey="Bower J" first="James H." last="Bower">James H. Bower</name><affiliation><mods:affiliation>Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA</mods:affiliation></affiliation></author><author><name sortKey="Burn, David J" sort="Burn, David J" uniqKey="Burn D" first="David J." last="Burn">David J. Burn</name><affiliation><mods:affiliation>Institute for Ageing and Health, Newcastle University,Newcastle Upon Tyne, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Low, Philip" sort="Low, Philip" uniqKey="Low P" first="Philip" last="Low">Philip Low</name><affiliation><mods:affiliation>Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota</mods:affiliation></affiliation></author><author><name sortKey="Jahanshahi, Marjan" sort="Jahanshahi, Marjan" uniqKey="Jahanshahi M" first="Marjan" last="Jahanshahi">Marjan Jahanshahi</name><affiliation><mods:affiliation>Institute of Neurology, University College London, London</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:D8D7BC0907EA1442286D43654D717164271E4C8E</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1002/mds.22794</idno><idno type="url">https://api.istex.fr/document/D8D7BC0907EA1442286D43654D717164271E4C8E/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">001B03</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy</title><author><name sortKey="Schrag, Anette" sort="Schrag, Anette" uniqKey="Schrag A" first="Anette" last="Schrag">Anette Schrag</name><affiliation><mods:affiliation>Institute of Neurology, University College London, London</mods:affiliation></affiliation></author><author><name sortKey="Sheikh, Shamira" sort="Sheikh, Shamira" uniqKey="Sheikh S" first="Shamira" last="Sheikh">Shamira Sheikh</name><affiliation><mods:affiliation>Institute of Neurology, University College London, London</mods:affiliation></affiliation></author><author><name sortKey="Quinn, Niall P" sort="Quinn, Niall P" uniqKey="Quinn N" first="Niall P." last="Quinn">Niall P. Quinn</name><affiliation><mods:affiliation>Institute of Neurology, University College London, London</mods:affiliation></affiliation></author><author><name sortKey="Lees, Andrew J" sort="Lees, Andrew J" uniqKey="Lees A" first="Andrew J." last="Lees">Andrew J. Lees</name><affiliation><mods:affiliation>Institute of Neurology, University College London, London</mods:affiliation></affiliation></author><author><name sortKey="Selai, Caroline" sort="Selai, Caroline" uniqKey="Selai C" first="Caroline" last="Selai">Caroline Selai</name><affiliation><mods:affiliation>Institute of Neurology, University College London, London</mods:affiliation></affiliation></author><author><name sortKey="Mathias, Chris" sort="Mathias, Chris" uniqKey="Mathias C" first="Chris" last="Mathias">Chris Mathias</name><affiliation><mods:affiliation>Institute of Neurology, University College London, London</mods:affiliation></affiliation><affiliation><mods:affiliation>Neurovascular Medicine Unit, Faculty of Medicine, Imperial College London, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Litvan, Irene" sort="Litvan, Irene" uniqKey="Litvan I" first="Irene" last="Litvan">Irene Litvan</name><affiliation><mods:affiliation>Movement Disorder Program, Department of Neurology, University of Louisville, Louisville, Kentucky, USA</mods:affiliation></affiliation></author><author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name><affiliation><mods:affiliation>Division of Neurology, Toronto Western Hospital and the University of Toronto, Toronto, Ontario, Canada</mods:affiliation></affiliation></author><author><name sortKey="Bower, James H" sort="Bower, James H" uniqKey="Bower J" first="James H." last="Bower">James H. Bower</name><affiliation><mods:affiliation>Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA</mods:affiliation></affiliation></author><author><name sortKey="Burn, David J" sort="Burn, David J" uniqKey="Burn D" first="David J." last="Burn">David J. Burn</name><affiliation><mods:affiliation>Institute for Ageing and Health, Newcastle University,Newcastle Upon Tyne, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Low, Philip" sort="Low, Philip" uniqKey="Low P" first="Philip" last="Low">Philip Low</name><affiliation><mods:affiliation>Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota</mods:affiliation></affiliation></author><author><name sortKey="Jahanshahi, Marjan" sort="Jahanshahi, Marjan" uniqKey="Jahanshahi M" first="Marjan" last="Jahanshahi">Marjan Jahanshahi</name><affiliation><mods:affiliation>Institute of Neurology, University College London, London</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2010-06-15">2010-06-15</date><biblScope unit="volume">25</biblScope><biblScope unit="issue">8</biblScope><biblScope unit="page" from="1077">1077</biblScope><biblScope unit="page" to="1081">1081</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">D8D7BC0907EA1442286D43654D717164271E4C8E</idno><idno type="DOI">10.1002/mds.22794</idno><idno type="ArticleID">MDS22794</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>anxiety</term><term>depression</term><term>health status</term><term>multiple system atrophy</term><term>parkinsonism</term><term>progressive supranuclear palsy</term><term>quality of life</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The objective of this study was to compare subjective health status and its correlates in progressive supranuclear palsy (PSP) and multiple system atrophy (MSA). One hundred eighty‐eight patients with PSP and 286 patients with MSA completed EQ‐5D and Hospital Depression and Anxiety Scale. The impact on mobility, usual activities, and self‐care was similarly high in both groups after similar duration. Fifty‐six percent of PSP and 43% of MSA had probable depression, and 37% of both groups had probable anxiety. Patients with PSP had significantly higher depression scores, but groups did not differ in anxiety scores. Patients with MSA had significantly greater pain/discomfort than patients with PSP. The most important association with subjective health status was with depressive symptoms, which accounted for 38% and 29% of EQ‐5D variance in patients with PSP and MSA, followed by disease severity and anxiety scores. We conclude that depressive symptoms were common in both disorders, but more severe in PSP. Anxiety symptoms affected 37% of patients in both groups and contributed to impaired subjective health status. Pain was more problematic in MSA than PSP. © 2010 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Anette Schrag MD, PhD</name><affiliations><json:string>Institute of Neurology, University College London, London</json:string></affiliations></json:item><json:item><name>Shamira Sheikh BSc</name><affiliations><json:string>Institute of Neurology, University College London, London</json:string></affiliations></json:item><json:item><name>Niall P. Quinn MD</name><affiliations><json:string>Institute of Neurology, University College London, London</json:string></affiliations></json:item><json:item><name>Andrew J. Lees MD</name><affiliations><json:string>Institute of Neurology, University College London, London</json:string></affiliations></json:item><json:item><name>Caroline Selai PhD</name><affiliations><json:string>Institute of Neurology, University College London, London</json:string></affiliations></json:item><json:item><name>Chris Mathias MD</name><affiliations><json:string>Institute of Neurology, University College London, London</json:string><json:string>Neurovascular Medicine Unit, Faculty of Medicine, Imperial College London, London, United Kingdom</json:string></affiliations></json:item><json:item><name>Irene Litvan MD</name><affiliations><json:string>Movement Disorder Program, Department of Neurology, University of Louisville, Louisville, Kentucky, USA</json:string></affiliations></json:item><json:item><name>Anthony E. Lang MD</name><affiliations><json:string>Division of Neurology, Toronto Western Hospital and the University of Toronto, Toronto, Ontario, Canada</json:string></affiliations></json:item><json:item><name>James H. Bower MD</name><affiliations><json:string>Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA</json:string></affiliations></json:item><json:item><name>David J. Burn MD</name><affiliations><json:string>Institute for Ageing and Health, Newcastle University,Newcastle Upon Tyne, United Kingdom</json:string></affiliations></json:item><json:item><name>Philip Low MD</name><affiliations><json:string>Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota</json:string></affiliations></json:item><json:item><name>Marjan Jahanshahi PhD</name><affiliations><json:string>Institute of Neurology, University College London, London</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>health status</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>multiple system atrophy</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>progressive supranuclear palsy</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>parkinsonism</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>depression</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>anxiety</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>quality of life</value></json:item></subject><articleId><json:string>MDS22794</json:string></articleId><language><json:string>eng</json:string></language><abstract>The objective of this study was to compare subjective health status and its correlates in progressive supranuclear palsy (PSP) and multiple system atrophy (MSA). One hundred eighty‐eight patients with PSP and 286 patients with MSA completed EQ‐5D and Hospital Depression and Anxiety Scale. The impact on mobility, usual activities, and self‐care was similarly high in both groups after similar duration. Fifty‐six percent of PSP and 43% of MSA had probable depression, and 37% of both groups had probable anxiety. Patients with PSP had significantly higher depression scores, but groups did not differ in anxiety scores. Patients with MSA had significantly greater pain/discomfort than patients with PSP. The most important association with subjective health status was with depressive symptoms, which accounted for 38% and 29% of EQ‐5D variance in patients with PSP and MSA, followed by disease severity and anxiety scores. We conclude that depressive symptoms were common in both disorders, but more severe in PSP. Anxiety symptoms affected 37% of patients in both groups and contributed to impaired subjective health status. Pain was more problematic in MSA than PSP. © 2010 Movement Disorder Society</abstract><qualityIndicators><score>7.208</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>7</keywordCount><abstractCharCount>1203</abstractCharCount><pdfWordCount>10987</pdfWordCount><pdfCharCount>73123</pdfCharCount><pdfPageCount>20</pdfPageCount><abstractWordCount>184</abstractWordCount></qualityIndicators><title>A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy</title><genre><json:string>article</json:string></genre><host><volume>25</volume><publisherId><json:string>MDS</json:string></publisherId><pages><total>5</total><last>1081</last><first>1077</first></pages><issn><json:string>0885-3185</json:string></issn><issue>8</issue><subject><json:item><value>Brief Report</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8257</json:string></eissn><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2010</publicationDate><copyrightDate>2010</copyrightDate><doi><json:string>10.1002/mds.22794</json:string></doi><id>D8D7BC0907EA1442286D43654D717164271E4C8E</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/D8D7BC0907EA1442286D43654D717164271E4C8E/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/D8D7BC0907EA1442286D43654D717164271E4C8E/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/D8D7BC0907EA1442286D43654D717164271E4C8E/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>WILEY</p></availability><date>2010</date></publicationStmt><notesStmt><note type="content">*Potential conflict of interest: None reported.</note><note>Society for Progressive Supranuclear Palsy</note><note>Sarah Matheson Trust for Multiple System Atrophy (UK)</note><note>The Progressive Supranuclear Palsy (PSP Europe) Association</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy</title><author><persName><forename type="first">Anette</forename><surname>Schrag</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>Institute of Neurology, University College London, London</affiliation></author><author><persName><forename type="first">Shamira</forename><surname>Sheikh</surname></persName><roleName type="degree">BSc</roleName><affiliation>Institute of Neurology, University College London, London</affiliation></author><author><persName><forename type="first">Niall P.</forename><surname>Quinn</surname></persName><roleName type="degree">MD</roleName><affiliation>Institute of Neurology, University College London, London</affiliation></author><author><persName><forename type="first">Andrew J.</forename><surname>Lees</surname></persName><roleName type="degree">MD</roleName><affiliation>Institute of Neurology, University College London, London</affiliation></author><author><persName><forename type="first">Caroline</forename><surname>Selai</surname></persName><roleName type="degree">PhD</roleName><affiliation>Institute of Neurology, University College London, London</affiliation></author><author><persName><forename type="first">Chris</forename><surname>Mathias</surname></persName><roleName type="degree">MD</roleName><affiliation>Institute of Neurology, University College London, London</affiliation><affiliation>Neurovascular Medicine Unit, Faculty of Medicine, Imperial College London, London, United Kingdom</affiliation></author><author><persName><forename type="first">Irene</forename><surname>Litvan</surname></persName><roleName type="degree">MD</roleName><affiliation>Movement Disorder Program, Department of Neurology, University of Louisville, Louisville, Kentucky, USA</affiliation></author><author><persName><forename type="first">Anthony E.</forename><surname>Lang</surname></persName><roleName type="degree">MD</roleName><affiliation>Division of Neurology, Toronto Western Hospital and the University of Toronto, Toronto, Ontario, Canada</affiliation></author><author><persName><forename type="first">James H.</forename><surname>Bower</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA</affiliation></author><author><persName><forename type="first">David J.</forename><surname>Burn</surname></persName><roleName type="degree">MD</roleName><affiliation>Institute for Ageing and Health, Newcastle University,Newcastle Upon Tyne, United Kingdom</affiliation></author><author><persName><forename type="first">Philip</forename><surname>Low</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota</affiliation></author><author><persName><forename type="first">Marjan</forename><surname>Jahanshahi</surname></persName><roleName type="degree">PhD</roleName><note type="correspondence"><p>Correspondence: Sobell Department of Motor Neuroscience and Movement Disorders, 33 Queen Square, London WC1N 3BG, United Kingdom</p></note><affiliation>Institute of Neurology, University College London, London</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2010-06-15"></date><biblScope unit="volume">25</biblScope><biblScope unit="issue">8</biblScope><biblScope unit="page" from="1077">1077</biblScope><biblScope unit="page" to="1081">1081</biblScope></imprint></monogr><idno type="istex">D8D7BC0907EA1442286D43654D717164271E4C8E</idno><idno type="DOI">10.1002/mds.22794</idno><idno type="ArticleID">MDS22794</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2010</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>The objective of this study was to compare subjective health status and its correlates in progressive supranuclear palsy (PSP) and multiple system atrophy (MSA). One hundred eighty‐eight patients with PSP and 286 patients with MSA completed EQ‐5D and Hospital Depression and Anxiety Scale. The impact on mobility, usual activities, and self‐care was similarly high in both groups after similar duration. Fifty‐six percent of PSP and 43% of MSA had probable depression, and 37% of both groups had probable anxiety. Patients with PSP had significantly higher depression scores, but groups did not differ in anxiety scores. Patients with MSA had significantly greater pain/discomfort than patients with PSP. The most important association with subjective health status was with depressive symptoms, which accounted for 38% and 29% of EQ‐5D variance in patients with PSP and MSA, followed by disease severity and anxiety scores. We conclude that depressive symptoms were common in both disorders, but more severe in PSP. Anxiety symptoms affected 37% of patients in both groups and contributed to impaired subjective health status. Pain was more problematic in MSA than PSP. © 2010 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>health status</term></item><item><term>multiple system atrophy</term></item><item><term>progressive supranuclear palsy</term></item><item><term>parkinsonism</term></item><item><term>depression</term></item><item><term>anxiety</term></item><item><term>quality of life</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Brief Report</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2009-01-26">Received</change><change when="2009-08-20">Registration</change><change when="2010-06-15">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/D8D7BC0907EA1442286D43654D717164271E4C8E/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="80"><doi origin="wiley" registered="yes">10.1002/mds.v25:8</doi><numberingGroup><numbering type="journalVolume" number="25">25</numbering><numbering type="journalIssue">8</numbering></numberingGroup><coverDate startDate="2010-06-15">15 June 2010</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="160" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.22794</doi><idGroup><id type="unit" value="MDS22794"></id></idGroup><countGroup><count type="pageTotal" number="5"></count></countGroup><titleGroup><title type="articleCategory">Brief Report</title><title type="tocHeading1">Brief Reports</title></titleGroup><copyright ownership="thirdParty">Copyright © 2010 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2009-01-26"></event><event type="manuscriptRevised" date="2009-08-20"></event><event type="manuscriptAccepted" date="2009-08-20"></event><event type="firstOnline" date="2010-04-13"></event><event type="publishedOnlineFinalForm" date="2010-06-09"></event><event type="publishedOnlineAcceptedOrEarlyUnpaginated" date="2010-04-13"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.4.7 mode:FullText source:FullText result:FullText" date="2011-02-24"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">1077</numbering><numbering type="pageLast">1081</numbering></numberingGroup><correspondenceTo>Sobell Department of Motor Neuroscience and Movement Disorders, 33 Queen Square, London WC1N 3BG, United Kingdom</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS22794.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="3"></count><count type="referenceTotal" number="25"></count><count type="wordTotal" number="4341"></count></countGroup><titleGroup><title type="main" xml:lang="en">A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy<link href="#fn1"></link></title><title type="short" xml:lang="en">Health‐Related Quality of Life in MSA and PSP</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Anette</givenNames><familyName>Schrag</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Shamira</givenNames><familyName>Sheikh</familyName><degrees>BSc</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Niall P.</givenNames><familyName>Quinn</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Andrew J.</givenNames><familyName>Lees</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Caroline</givenNames><familyName>Selai</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af1 #af2"><personName><givenNames>Chris</givenNames><familyName>Mathias</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au7" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Irene</givenNames><familyName>Litvan</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au8" creatorRole="author" affiliationRef="#af4"><personName><givenNames>Anthony E.</givenNames><familyName>Lang</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au9" creatorRole="author" affiliationRef="#af5"><personName><givenNames>James H.</givenNames><familyName>Bower</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au10" creatorRole="author" affiliationRef="#af6"><personName><givenNames>David J.</givenNames><familyName>Burn</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au11" creatorRole="author" affiliationRef="#af7"><personName><givenNames>Philip</givenNames><familyName>Low</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au12" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Marjan</givenNames><familyName>Jahanshahi</familyName><degrees>PhD</degrees></personName><contactDetails><email>m.jahanshahi@ion.ucl.ac.uk</email></contactDetails></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="GB" type="organization"><unparsedAffiliation>Institute of Neurology, University College London, London</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="GB" type="organization"><unparsedAffiliation>Neurovascular Medicine Unit, Faculty of Medicine, Imperial College London, London, United Kingdom</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="US" type="organization"><unparsedAffiliation>Movement Disorder Program, Department of Neurology, University of Louisville, Louisville, Kentucky, USA</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="CA" type="organization"><unparsedAffiliation>Division of Neurology, Toronto Western Hospital and the University of Toronto, Toronto, Ontario, Canada</unparsedAffiliation></affiliation><affiliation xml:id="af5" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA</unparsedAffiliation></affiliation><affiliation xml:id="af6" countryCode="GB" type="organization"><unparsedAffiliation>Institute for Ageing and Health, Newcastle University,Newcastle Upon Tyne, United Kingdom</unparsedAffiliation></affiliation><affiliation xml:id="af7" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">health status</keyword><keyword xml:id="kwd2">multiple system atrophy</keyword><keyword xml:id="kwd3">progressive supranuclear palsy</keyword><keyword xml:id="kwd4">parkinsonism</keyword><keyword xml:id="kwd5">depression</keyword><keyword xml:id="kwd6">anxiety</keyword><keyword xml:id="kwd7">quality of life</keyword></keywordGroup><fundingInfo><fundingAgency>Society for Progressive Supranuclear Palsy</fundingAgency></fundingInfo><fundingInfo><fundingAgency>Sarah Matheson Trust for Multiple System Atrophy (UK)</fundingAgency></fundingInfo><fundingInfo><fundingAgency>The Progressive Supranuclear Palsy (PSP Europe) Association</fundingAgency></fundingInfo><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>The objective of this study was to compare subjective health status and its correlates in progressive supranuclear palsy (PSP) and multiple system atrophy (MSA). One hundred eighty‐eight patients with PSP and 286 patients with MSA completed EQ‐5D and Hospital Depression and Anxiety Scale. The impact on mobility, usual activities, and self‐care was similarly high in both groups after similar duration. Fifty‐six percent of PSP and 43% of MSA had probable depression, and 37% of both groups had probable anxiety. Patients with PSP had significantly higher depression scores, but groups did not differ in anxiety scores. Patients with MSA had significantly greater pain/discomfort than patients with PSP. The most important association with subjective health status was with depressive symptoms, which accounted for 38% and 29% of EQ‐5D variance in patients with PSP and MSA, followed by disease severity and anxiety scores. We conclude that depressive symptoms were common in both disorders, but more severe in PSP. Anxiety symptoms affected 37% of patients in both groups and contributed to impaired subjective health status. Pain was more problematic in MSA than PSP. © 2010 Movement Disorder Society</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn1"><p>Potential conflict of interest: None reported.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Health‐Related Quality of Life in MSA and PSP</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy</title></titleInfo><name type="personal"><namePart type="given">Anette</namePart><namePart type="family">Schrag</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Institute of Neurology, University College London, London</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Shamira</namePart><namePart type="family">Sheikh</namePart><namePart type="termsOfAddress">BSc</namePart><affiliation>Institute of Neurology, University College London, London</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Niall P.</namePart><namePart type="family">Quinn</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Institute of Neurology, University College London, London</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Andrew J.</namePart><namePart type="family">Lees</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Institute of Neurology, University College London, London</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Caroline</namePart><namePart type="family">Selai</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Institute of Neurology, University College London, London</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Chris</namePart><namePart type="family">Mathias</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Institute of Neurology, University College London, London</affiliation><affiliation>Neurovascular Medicine Unit, Faculty of Medicine, Imperial College London, London, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Irene</namePart><namePart type="family">Litvan</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Movement Disorder Program, Department of Neurology, University of Louisville, Louisville, Kentucky, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Anthony E.</namePart><namePart type="family">Lang</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Division of Neurology, Toronto Western Hospital and the University of Toronto, Toronto, Ontario, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">James H.</namePart><namePart type="family">Bower</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">David J.</namePart><namePart type="family">Burn</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Institute for Ageing and Health, Newcastle University,Newcastle Upon Tyne, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Philip</namePart><namePart type="family">Low</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Marjan</namePart><namePart type="family">Jahanshahi</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Institute of Neurology, University College London, London</affiliation><description>Correspondence: Sobell Department of Motor Neuroscience and Movement Disorders, 33 Queen Square, London WC1N 3BG, United Kingdom</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2010-06-15</dateIssued><dateCaptured encoding="w3cdtf">2009-01-26</dateCaptured><dateValid encoding="w3cdtf">2009-08-20</dateValid><copyrightDate encoding="w3cdtf">2010</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="tables">3</extent><extent unit="references">25</extent><extent unit="words">4341</extent></physicalDescription><abstract lang="en">The objective of this study was to compare subjective health status and its correlates in progressive supranuclear palsy (PSP) and multiple system atrophy (MSA). One hundred eighty‐eight patients with PSP and 286 patients with MSA completed EQ‐5D and Hospital Depression and Anxiety Scale. The impact on mobility, usual activities, and self‐care was similarly high in both groups after similar duration. Fifty‐six percent of PSP and 43% of MSA had probable depression, and 37% of both groups had probable anxiety. Patients with PSP had significantly higher depression scores, but groups did not differ in anxiety scores. Patients with MSA had significantly greater pain/discomfort than patients with PSP. The most important association with subjective health status was with depressive symptoms, which accounted for 38% and 29% of EQ‐5D variance in patients with PSP and MSA, followed by disease severity and anxiety scores. We conclude that depressive symptoms were common in both disorders, but more severe in PSP. Anxiety symptoms affected 37% of patients in both groups and contributed to impaired subjective health status. Pain was more problematic in MSA than PSP. © 2010 Movement Disorder Society</abstract><note type="content">*Potential conflict of interest: None reported.</note><note type="funding">Society for Progressive Supranuclear Palsy</note><note type="funding">Sarah Matheson Trust for Multiple System Atrophy (UK)</note><note type="funding">The Progressive Supranuclear Palsy (PSP Europe) Association</note><subject lang="en"><genre>Keywords</genre><topic>health status</topic><topic>multiple system atrophy</topic><topic>progressive supranuclear palsy</topic><topic>parkinsonism</topic><topic>depression</topic><topic>anxiety</topic><topic>quality of life</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><genre type="Journal">journal</genre><subject><genre>article category</genre><topic>Brief Report</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><detail type="issue"><caption>no.</caption><number>8</number></detail><extent unit="pages"><start>1077</start><end>1081</end><total>5</total></extent></part></relatedItem><identifier type="istex">D8D7BC0907EA1442286D43654D717164271E4C8E</identifier><identifier type="DOI">10.1002/mds.22794</identifier><identifier type="ArticleID">MDS22794</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2010 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001B03 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001B03 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:D8D7BC0907EA1442286D43654D717164271E4C8E
|texte= A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy
}}
| This area was generated with Dilib version V0.6.23. |  |